Precision’s Tomas Philipson in his regular column in Forbes.com, talks about the precision medicine initiative as a more useful approach towards appropriate adherence behavior.
In the May cover story: “Exploring Precision Medicine’s Value” Dan Renick discusses the value of specialized treatments. He contends that precision medicine in the face of limited resources necessitates evidence generation that supports the value of therapeutic breakthroughs. The in-depth article explores the value of precision medicine from a research, governmental and managed care perspective.
In Health Affairs, PHE’s Goldman and Lakdawalla suggest it’s time for value-based payment in oncology.
Los Angeles, CA, April 27, 2015—Precision Health Economics (PHE), a Precision for Medicine company, announced today the hiring of James Baumgardner, PhD, as Senior Research Economist. Joining PHE from his post as Deputy Assistant Director in the Health, Retirement, and Long-Term Analysis Division of the Congressional Budget Office (CBO), Mr. Baumgardner brings unique experiences and perspectives to the complex and challenging problems PHE addresses in its work on health economics and policy. PHE is focused on the critical issues in health and healthcare delivery: objective determination of value and measureable improvement in patient outcomes.
This real-world study measures the impact of a field force on market access when provided with physician-specific access opportunities and corresponding, personalized pull-through messages.
Precision offers an in-person, executive briefing series on critical issues affecting value propositions and market access. Insights to Access is available to select groups. Contact us for details. Insights to Access is an interactive, dynamic series of presentations featuring former payers who are now on the Precision Payer Strategy Team. They share knowledge and tactics regarding the latest payer trends, legislation, and market developments. These presentations foster a productive discussion that will help prepare your team to succeed as they face the most pressing issues in payer marketing today.
As healthcare spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important. This research brief shares novel, groundbreaking studies that have helped define the value of new oncology drugs, and recommends new criteria for framing value in cancer care.
The recent entry of biosimilar anti-TNFs into the European markets has attracted considerable attention—much of it centered on competitive discounting. Yet proprietary research with key payers and clinicians from 9 European countries shows that customer decisions are largely not based on price. Discover the initiatives that can incentivize these influential decision-makers and when to most effectively leverage each in the decision-making chain.